Cosmo Pharmaceuticals (CMOPF) News Today C$75.00 0.00 (0.00%) As of 08/29/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock CMOPF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cosmo Pharmaceuticals Gains CHMP Approval for Winlevi® in EuropeAugust 27 at 6:10 AM | msn.comCosmo Receives Positive CHMP Opinion for Winlevi(R) for Treatment of Acne in Adults and Adolescents, Following Successful Re-ExaminationAugust 27 at 6:10 AM | finance.yahoo.comCosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth MomentumAugust 7, 2025 | finance.yahoo.comCosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. ...August 6, 2025 | gurufocus.comCosmo Pharmaceuticals Unaffected by US Tariffs, Maintains Growth MomentumAugust 6, 2025 | tipranks.comCosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and DermatologyJuly 24, 2025 | finance.yahoo.comCosmo Pharmaceuticals N.V. GAAP EPS of -€0.12, revenue of €51.72MJuly 23, 2025 | seekingalpha.comCosmo Accelerates Global ESG Leadership with Major Ratings Upgrades, UN Compact Commitment, and Climate Action PledgeJuly 16, 2025 | finance.yahoo.comCosmo Pharmaceuticals Advances ESG Leadership with Key InitiativesJuly 16, 2025 | tipranks.comCosmo Pharmaceuticals Sells ‘Digital Trust’ to Tinexta InfoCertJune 25, 2025 | tipranks.comCosmo Pharmaceuticals’ 2025 General Meeting Approves Dividend IncreaseMay 30, 2025 | tipranks.comCosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025May 5, 2025 | theglobeandmail.comCosmo Pharmaceuticals Advances AI and GI Drug Development at DDW 2025May 5, 2025 | tipranks.comCosmo Pharmaceuticals’ AI-Powered Cerebro Receives EU-MDR CertificationMay 2, 2025 | tipranks.comCosmo Publishes Agenda of AGM 2025April 29, 2025 | finance.yahoo.comCosmo Pharmaceuticals Announces Agenda for 2025 General MeetingApril 29, 2025 | tipranks.comCosmo Pharmaceuticals to Appeal EMA’s Negative Opinion on Winlevi®April 29, 2025 | tipranks.comCosmo Pharmaceuticals Appoints New Chief Legal CounselApril 1, 2025 | tipranks.comCosmo Pharmaceuticals publishes Annual Report 2024March 27, 2025 | theglobeandmail.comCosmo Pharmaceuticals reports FY resultsMarch 21, 2025 | seekingalpha.comFull Year 2024 Cosmo Pharmaceuticals NV Earnings Call TranscriptMarch 7, 2025 | gurufocus.comCosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...March 7, 2025 | gurufocus.comCosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across PortfolioFebruary 11, 2025 | finance.yahoo.comCosmo names Andrea Cherubini as chief AI officerFebruary 11, 2025 | msn.comGlenmark, Cosmo get MHRA nod for acne treatment medicationFebruary 10, 2025 | msn.comCosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of AcneFebruary 10, 2025 | finance.yahoo.comCosmo, Glenmark secure UK MHRA approval of Winlevi for treatment of acneFebruary 10, 2025 | msn.comKepler Capital Sticks to Its Buy Rating for COSMO Pharmaceuticals N.V. (0RGI)January 11, 2025 | markets.businessinsider.comCosmo Pharmaceuticals Appoints Chief Strategy OfficerDecember 12, 2024 | finance.yahoo.comCosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGMOctober 19, 2024 | stockhouse.comCosmo Pharmaceuticals Appoints New Chief Financial OfficerOctober 11, 2024 | stockhouse.comCosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...October 9, 2024 | finance.yahoo.comCosmo Chemical Co LtdSeptember 20, 2024 | reuters.comCMOPF Cosmo Pharmaceuticals N.V.September 7, 2024 | seekingalpha.comFree food, endless TV and… the flu? This is what it’s like to take part in a paid medical trialAugust 11, 2024 | msn.comCosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA ClearanceJuly 31, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. (CMOPF)July 26, 2024 | ca.finance.yahoo.comCosmo Pharmaceuticals NV's Dividend AnalysisMay 27, 2024 | finance.yahoo.comCosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General MeetingMay 24, 2024 | finance.yahoo.comCosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023April 29, 2024 | finance.yahoo.comDespite concern about older adults living alone, these seniors prefer the solo life: 'I love not having to answer to anyone else'April 29, 2024 | msn.comCosmo Announces Leadership ChangesApril 25, 2024 | finance.yahoo.comQ4 2023 Paysign Inc Earnings CallMarch 28, 2024 | finance.yahoo.comBullish: Analysts Just Made A Massive Upgrade To Their Cosmo Pharmaceuticals N.V. (VTX:COPN) ForecastsMarch 28, 2024 | finance.yahoo.comCosmo Pharmaceuticals N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 23, 2024 | finance.yahoo.comCosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per ShareMarch 20, 2024 | finance.yahoo.comCosmo Pharmaceuticals Announces Approval of Winlevi(R) in AustraliaMarch 19, 2024 | finance.yahoo.comSay Hi to the Cosmo Trend Report: A Comprehensive Look at All the Things You’re Gonna Want to Wear This SpringMarch 15, 2024 | msn.comCosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 18% loss from investing in the stock three years agoMarch 13, 2024 | finance.yahoo.comGibson to open huge guitar store in West End on SaturdayFebruary 23, 2024 | msn.com Get Cosmo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMOPF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMOPF Media Mentions By Week CMOPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMOPF News Sentiment▼1.491.05▲Average Medical News Sentiment CMOPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMOPF Articles This Week▼20▲CMOPF Articles Average Week Get the Latest News and Ratings for CMOPF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cosmo Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AstraZeneca News Today CSPC Pharmaceutical Group News Today JCR Pharmaceuticals News Today Kyowa Kirin News Today Mayne Pharma Group News Today Ono Pharmaceutical News Today Otsuka News Today Roche News Today Sanofi News Today Scilex News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTC:CMOPF) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cosmo Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Share Cosmo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
